AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update

AlloVir, Inc. (NASDAQ:ALVR) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 1,260,000 shares, a decline of 25.4% from the December 15th total of 1,690,000 shares. Based on an average trading volume of 370,200 shares, the days-to-cover ratio is presently 3.4 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in AlloVir stock. Cubist Systematic Strategies LLC grew its holdings in shares of AlloVir, Inc. (NASDAQ:ALVR) by 152.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 49,816 shares of the company’s stock after acquiring an additional 30,072 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in AlloVir were worth $36,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 66.05% of the company’s stock.

AlloVir Price Performance

AlloVir stock opened at $0.38 on Thursday. The firm has a market capitalization of $44.04 million, a P/E ratio of -0.43 and a beta of 0.65. AlloVir has a one year low of $0.38 and a one year high of $1.05. The business has a fifty day moving average price of $0.52 and a 200-day moving average price of $0.69.

AlloVir (NASDAQ:ALVR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.